Outcomes of phacoemulsification in patients with uveitis at a tertiary center in São Paulo, Brazil: a review of cases from 2007 to 2012.

PURPOSE:: To evaluate the outcomes of phacoemulsification with intraocular lens (IOL) implantation in eyes with uveitis. METHODS:: Consecutive patients with uveitis and cataracts who had phacoemulsification and acrylic IOL implantation during 2007-2012 were evaluated for visual outcomes, etiology, and complications. Inflammation was controlled for at least 3 months before surgery, and oral prednisone (0.5 mg/kg/day) was administered to patients with non-infectious uveitis. RESULTS:: This study investigated 45 eyes in 38 patients with a mean age of 52 ± 12.5 years. The most common etiologies among non-infectious causes (n=32; 73.3%) were Vogt-Koyanagi-Harada disease (n=9), Fuchs heterochromic iridocyclitis (n=4), and sympathetic ophthalmia (n=3). Four cases were idiopathic. Among infectious cases (n=13; 28.9%), the most common causes were toxoplasmosis (n=6) and presumed ocular tuberculosis (n=4). An acrylic IOL was implanted in-the-bag in all cases. After 1-year follow-up, an improvement in visual acuity of two or more lines was observed in 38 eyes (84.4%), and 28 eyes (62.2%) achieved a postoperative visual acuity of ≥0.5. Posterior capsule opacification was observed in 10 eyes (22.2%). Persistent postoperative inflammation (of >6 months) was observed in seven eyes (15.5%) and recurrence occurred in four eyes (8.8%). IOL was explanted in one eye. Intraocular hypertension was observed in six eyes (13.3%). CONCLUSIONS:: Phacoemulsification with IOL implantation improved vision in most patients with coexisting cataracts and uveitis. Good preoperative and postoperative control of inflammation plays an important role in achieving favorable visual outcomes. Furthermore, the final visual outcome depends on the posterior segment status.

Outcomes of phacoemulsification in patients with uveitis at a tertiary center in São Paulo, Brazil: a review of cases from 2007 to 2012 / Resultado da facoemulsificação em pacientes com uveíte em um centro terciário em São Paulo, Brasil: revisão de casos de 2007 a 2012

ABSTRACT Purpose: To evaluate the outcomes of phacoemulsification with intraocular lens (IOL) implantation in eyes with uveitis. Methods: Consecutive patients with uveitis and cataracts who had phacoemulsification and acrylic IOL implantation during 2007-2012 were evaluated for visual outcomes, etiology, and complications. Inflammation was controlled for at least 3 months before surgery, and oral prednisone (0.5 mg/kg/day) was administered to patients with non-infectious uveitis. Results: This study investigated 45 eyes in 38 patients with a mean age of 52 ± 12.5 years. The most common etiologies among non-infectious causes (n=32; 73.3%) were Vogt-Koyanagi-Harada disease (n=9), Fuchs heterochromic iridocyclitis (n=4), and sympathetic ophthalmia (n=3). Four cases were idiopathic. Among infectious cases (n=13; 28.9%), the most common causes were toxoplasmosis (n=6) and presumed ocular tuberculosis (n=4). An acrylic IOL was implanted in-the-bag in all cases. After 1-year follow-up, an improvement in visual acuity of two or more lines was observed in 38 eyes (84.4%), and 28 eyes (62.2%) achieved a postoperative visual acuity of ≥0.5. Posterior capsule opacification was observed in 10 eyes (22.2%). Persistent postoperative inflammation (of >6 months) was observed in seven eyes (15.5%) and recurrence occurred in four eyes (8.8%). IOL was explanted in one eye. Intraocular hypertension was observed in six eyes (13.3%). Conclusions: Phacoemulsification with IOL implantation improved vision in most patients with coexisting cataracts and uveitis. Good preoperative and postoperative control of inflammation plays an important role in achieving favorable visual outcomes. Furthermore, the final visual outcome depends on the posterior segment status.

RESUMO Objetivos: Avaliar os resultados da facoemulsificação com implante de lente intraocular em olhos com uveíte. Métodos: Foram incluídos pacientes consecutivos com catarata e uveíte, submetidos a facoemulsificação com implante de lente intraocular acrílica no período de 2007 a 2012, onde avaliou-se resultados visuais, etiologia e complicações. A inflamação estava quiescente por pelo menos três meses e foi usado prednisona oral (0,5 mg/kg/dia) em pacientes com uveíte não infecciosa. Resultados: Este estudo incluiu 45 olhos de 38 pacientes com idade media de 52±12.5 anos. As etiologias mais frequentes, entre as causas não-infecciosas (n=32; 73,3%), foram doença de Vogt-Koyanagi-Harada (n=9), idiopáticas (n=4), iridociclite heterocrômica de Fuchs (n=4) e oftalmia simpática (n=3). Entre as causas infecciosas (n=13; 28,9%), as mais frequentes foram toxoplamose (n=6) e tuberculose ocular presumida (n=4). Uma lente de acrílico foi implantada no saco capsular em todos os casos. Com um ano de seguimento, 38 olhos (84,4%) melhoraram 2 ou mais linhas; 28 olhos (62,2%) atingiram uma acuidade visual pós-operatória de 0,5 ou melhor. Opacidade de cápsula posterior foi observada em 10 olhos (22,2%). Inflamação pós-operatória persistente (>6 meses) foi observada em 7 olhos (15,5%) e a recorrência ocorreu em 4 olhos (8,8%). Houve necessidade de explante da lente em um olho. Hipertensão intraocular foi observada em 6 olhos (13,3%). Conclusões: Facoemulsificação com implante de lente intraocular melhorou a visão na maioria dos pacientes com catarata e uveíte. O controle adequado pré e pós-operatório da inflamação desempenha um papel reconhecidamente importante para obtenção de bons resultados visuais. O resultado visual final depende de alterações prévias do segmento posterior.

Mycophenolate mofetil as an immunomodulator in refractory noninfectious uveitis / Micofenolato mofetila como agente imunomodulador no tratamento das uveítes não infecciosas refratárias

ABSTRACT Purpose: To evaluate the efficacy and tolerance of mycophenolate mofetil (MMF) for the treatment of noninfectious uveitis using the methods advocated by the Standardization of Uveitis Nomenclature (SUN) Working Group and to compare this with other studies of immunosuppression in ocular inflammation. Methods: Retrospective case series. Patients with noninfectious uveitis, followed at a tertiary Uveitis Service in São Paulo, Brazil, from 2007 to 2014 and receiving oral MMF for a minimum of 6 months, were retrospectively reviewed. After reaching an optimal dose of MMF, patients were evaluated after 6 (T6), 12 (T12), and 24 months (T24). The optimal dose varied for each patient (medium 2.2 g/day, range 1.0-3.0 g/day). The main outcome measures were: 1) success on achieving complete control of inflammation in both eyes and/or oral prednisone dosage reduction to ≤10 mg per day, and 2) the length of time required to reduce oral prednisone to ≤10 mg/day, partial control of ocular inflammation, and side effects. Results: In a cohort of 16 patients with refractory noninfectious uveitis, 67% reached the ideal prednisone dose after 1 year of MMF treatment and 83% after 2 years of MMF treatment. Complete or partial inflammation control was achieved in 43.7% at T12. Two patients (14%) had disease remission after 4.7 years of MMF treatment. Adverse effects were gastrointestinal disturbances, infection, insomnia, and liver function abnormalities at a rate of 0.03 patient-year each. Conclusions: This small retrospective case series is consistent with the literature concerning the high efficacy and moderate tolerability of MMF in noninfectious uveitis. Observation of patients should be continued for at least 1 year to clearly determine MMF efficacy.

RESUMO Objetivo: Avaliar a eficácia e tolerância do micofenolato de mofetila (MMF) para o tratamento das uveítes não infecciosas refratárias, utilizando os métodos de análises definidos pelo "Standardization of Uveitis Nomenclature Working Group." Método: Estudo retrospectivo de série de casos. Foram incluídos pacientes com uveíte não infecciosa, em tratamento oral com MMF por um período mínimo de seis meses, acompanhados no Serviço de Uveítes, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brasil, no período de 2007 a 2014. Todos os pacientes faziam uso de pelo menos um imunossupressor e apresentavam doença ocular ativa. Os pacientes foram avaliados aos seis meses (T6), 12 meses (T12) e 24 meses (T24) após atingir a dose ótima do MMF. A média da dose ótima foi 2,2g/dia (intervalo 1,0-3,0g/dia). Os principais desfechos analisados foram: 1) Sucesso no controle total da inflamação em ambos os olhos e/ou redução da dose de prednisona oral para ≤10 mg/dia; 2) Intervalo até a redução da prednisona oral para ≤10 mg/dia, controle parcial de inflamação ocular e efeitos adversos. Resultados: Na presente coorte com 16 pacientes com uveíte não infecciosa refratária, observou-se 67% e 83% de probabilidade de alcançar a dose ideal de prednisona em T12 e T24, respectivamente. Controle total ou parcial da inflamação foi observado em 43,7% dos pacientes em T12. Dois pacientes (14%) tiveram remissão da doença após 4,7 anos do início de MMF. Os efeitos adversos foram distúrbios gastrintestinais, infecção, insônia e anormalidade da função hepática com 0,03 eventos paciente-ano (PPY) respectivamente. Conclusões: Esta pequena série retrospectiva de casos ratifica os achados na literatura sobre a alta eficácia e tolerância moderada de MMF em uveítes não infecciosas. Uma importante observação é que, para melhor avaliar a eficácia do MMF, deve se esperar o intervalo mínimo de um ano.

Mycophenolate mofetil as an immunomodulator in refractory noninfectious uveitis.

PURPOSE:: To evaluate the efficacy and tolerance of mycophenolate mofetil (MMF) for the treatment of noninfectious uveitis using the methods advocated by the Standardization of Uveitis Nomenclature (SUN) Working Group and to compare this with other studies of immunosuppression in ocular inflammation. METHODS:: Retrospective case series. Patients with noninfectious uveitis, followed at a tertiary Uveitis Service in São Paulo, Brazil, from 2007 to 2014 and receiving oral MMF for a minimum of 6 months, were retrospectively reviewed. After reaching an optimal dose of MMF, patients were evaluated after 6 (T6), 12 (T12), and 24 months (T24). The optimal dose varied for each patient (medium 2.2 g/day, range 1.0-3.0 g/day). The main outcome measures were: 1) success on achieving complete control of inflammation in both eyes and/or oral prednisone dosage reduction to ≤10 mg per day, and 2) the length of time required to reduce oral prednisone to ≤10 mg/day, partial control of ocular inflammation, and side effects. RESULTS:: In a cohort of 16 patients with refractory noninfectious uveitis, 67% reached the ideal prednisone dose after 1 year of MMF treatment and 83% after 2 years of MMF treatment. Complete or partial inflammation control was achieved in 43.7% at T12. Two patients (14%) had disease remission after 4.7 years of MMF treatment. Adverse effects were gastrointestinal disturbances, infection, insomnia, and liver function abnormalities at a rate of 0.03 patient-year each. CONCLUSIONS:: This small retrospective case series is consistent with the literature concerning the high efficacy and moderate tolerability of MMF in noninfectious uveitis. Observation of patients should be continued for at least 1 year to clearly determine MMF efficacy.

Enhanced depth imaging optical coherence tomography in long-standing Vogt-Koyanagi-Harada disease.

AIM: To evaluate the choroidal thickness (CT) in patients with long-standing Vogt-Koyanagi-Harada (VKH) disease using enhanced depth imaging optical coherence tomography (EDI-OCT). METHODS: A prospective case-control study developed at a tertiary centre at São Paulo, Brazil. EDI-OCT images were obtained in 16 patients (30 eyes) with VKH disease who had had the disease for more than 6 months since disease onset, and in 17 normal individuals controlled by age (32 eyes). Comprehensive ophthalmic examination and EDI-OCT evaluation were performed. CT was measured at the fovea and at 1000 µm intervals from the foveal centre in both temporal and nasal directions. CT was correlated with disease duration, clinical disease activity and fundus-based disease severity. RESULTS: Mean subfoveal CT was 333 µm (±85.8) in controls and 250.7 µm (±93.3) in VKH patients (p=0.002). The choroid was significantly thinner in patients when compared to controls in all but one nasal point. In patients, the CT measurements at the foveal centre presented a negative correlation with disease duration (p<0.001). No significant difference in CT measurements was observed between eyes with and without clinical inflammation (p=0.42). There was a trend towards more severe fundus changes being associated with a thinner choroid (p=0.28). CONCLUSIONS: Patients with VKH and long-standing disease had thinner choroids when compared to controls. Progressive choroidal thinning related to disease duration was observed at the macula of these patients. Whether this finding is part of the natural history of the disease or the result of a clinically undetected choroidal inflammation remains to be determined.

Indocyanine green angiography findings in patients with long-standing Vogt-Koyanagi-Harada disease: a cross-sectional study.

BACKGROUND: To investigate indocyanine green angiography (ICGA) findings in patients with long-standing Vogt-Koyanagi-Harada (VKH) disease and their correlation with disease activity on clinical examination as well as with systemic corticosteroid therapy. METHODS: Twenty-eight patients (51 eyes) with long-standing (≥6 months from disease onset) VKH disease whose treatment was tapered based only in clinical features were prospectively included at a single center in Brazil. All patients underwent standardized clinical evaluation, which included fundus photography, fluorescein angiography and ICGA. Clinical disease activity was determined based in the Standardization in Uveitis Nomenclature Working Group. Fisher exact test and logistic regression models were used for statistical analysis. RESULTS: Disease-related choroidal inflammation on ICGA was observed in 72.5% (31 of 51 eyes). Angiographic findings suggestive of (choroidal and/or retinal) disease activity were not observed on FA. Clinically active disease based on clinical evaluation was observed in 41.2% (21 of 51 eyes). In these 21 eyes, disease-related choroidal inflammation on ICGA was observed in 76.2% (16 of 21 eyes); in the remaining eyes (without clinical active disease) disease-related choroidal inflammation on ICGA was observed in 70.0% (21 of 30 eyes). In respect to systemic corticosteroid therapy, 10 patients (18 of 51 eyes) were under treatment with prednisone. In these 10 (18 of 51 eyes) patients, disease-related choroidal inflammation on ICGA was observed in 83.3% (15 of 18 eyes); in the remaining patients (33 of 51 eyes) disease-related choroidal inflammation on ICGA was observed in 66.7% (22 of 33 eyes). CONCLUSION: ICGA findings suggestive of disease-related choroidal inflammation were observed in a considerable proportion of patients with long-standing VKH disease, independent of the inflammatory status of the disease on clinical examination or current use of systemic corticosteroid. Therefore, the current study reinforces the crucial role of ICGA to assist the management and treatment of patients with long-standing VKH disease.

Chlorambucil and cyclosporine A in Brazilian patients with Behçet's disease uveitis: a retrospective study.

PURPOSE: To assess the efficacy and side effects of immunosuppressive therapy in patients with Behçet's disease uveitis. METHODS: A nonrandomized retrospective case-series study analyzed data from 22 patients with Behçet's disease uveitis, from a single Uveitis Service, São Paulo, Brazil (period 1978-2007), under systemic chlorambucil and/or cyclosporine A, for at least 6 months with a minimum one-year follow-up. Drug efficacy was measured by reduction in relapse rate and reduction of prednisone dose. RESULTS: Patients (10M/12F) mean age was 29 (range 10-43) years-old at the onset of uveitis. The median duration of followup was 11 (range 1-29) years-old. Chlorambucil (2-6 mg/day) was used in 13 patients and cyclosporine A (3-5 mg/kg/day) in 9 patients at initiation. Drugs were switched because of no effectiveness or side-effects. Chlorambucil was effective in 78.5% (11/14) and induced disease remission in 43% (6/14) of patients, whereas cyclosporine A was effective in 57% (8/14) of patients. Chlorambucil and cyclosporine A were discontinued due to side effects in 21% (leucopenia) and in 57% of patients (nephrotoxicity, 36% and gastrointestinal complications, 21%), respectively. No case of late malignancy was observed. 36% (16/44) of eyes had final visual acuity < or =0.1, among which 69% (11/16) had already this visual acuity at the first visit. CONCLUSION: This study reiterates previous data that chlorambucil can induce long-term remission of Behçet's disease uveitis, whereas cyclosporine is effective but side effects limit its use. Chlorambucil therapy may still be a reasonable option in patients with intractable, sight-threatening Behçet's disease uveitis.

Chlorambucil and cyclosporine A in Brazilian patients with Behçet's disease uveitis: a retrospective study / Clorambucil e ciclosporina A em pacientes brasileiros com doença de Behçet e uveíte: estudo retrospectivo

PURPOSE: To assess the efficacy and side effects of immunosuppressive therapy in patients with Behçet's disease uveitis. METHODS: A nonrandomized retrospective case-series study analyzed data from 22 patients with Behçet's disease uveitis, from a single Uveitis Service, São Paulo, Brazil (period 1978-2007), under systemic chlorambucil and/or cyclosporine A, for at least 6 months with a minimum one-year follow-up. Drug efficacy was measured by reduction in relapse rate and reduction of prednisone dose. RESULTS: Patients (10M/12F) mean age was 29 (range 10-43) years-old at the onset of uveitis. The median duration of followup was 11 (range 1-29) years-old. Chlorambucil (2-6 mg/day) was used in 13 patients and cyclosporine A (3-5 mg/kg/day) in 9 patients at initiation. Drugs were switched because of no effectiveness or side-effects. Chlorambucil was effective in 78.5 percent (11/14) and induced disease remission in 43 percent (6/14) of patients, whereas cyclosporine A was effective in 57 percent (8/14) of patients. Chlorambucil and cyclosporine A were discontinued due to side effects in 21 percent (leucopenia) and in 57 percent of patients (nephrotoxicity, 36 percent and gastrointestinal complications, 21 percent), respectively. No case of late malignancy was observed. 36 percent (16/44) of eyes had final visual acuity <0.1, among which 69 percent (11/16) had already this visual acuity at the first visit. CONCLUSION: This study reiterates previous data that chlorambucil can induce long-term remission of Behçet's disease uveitis, whereas cyclosporine is effective but side effects limit its use. Chlorambucil therapy may still be a reasonable option in patients with intractable, sight-threatening Behçet's disease uveitis.

OBJETIVOS: Avaliar a eficácia e efeitos colaterais da terapia imunossupressora em pacientes com uveíte associada à doença de Behçet. MÉTODOS: Estudo retrospectivo não randomizado no qual são analisados dados de 22 pacientes com uveíte associada à doença de Behçet que utilizaram clorambucil e/ou ciclosporina A sistêmica por período mínimo de 6 meses, acompanhados pelo período mínimo de 1 ano, num único Serviço de Uveíte, São Paulo, Brasil (período 1978-2007). A eficácia do tratamento foi avaliada pela redução no número de recidivas da inflamação e pela redução na dose diária de prednisona. RESULTADOS: Vinte e dois pacientes (10 M/12 F), com idade média de 29 (variação 10-43) anos, apresentaram tempo mediano de acompanhamento de 11 (variação 1-29) anos. Clorambucil (2-6 mg/dia) foi utilizado em 13 pacientes e ciclosporina A (3-5 mg/kg/dia) em 9 pacientes como droga de primeira escolha. As drogas foram substituídas quando não eficazes ou não toleradas devido a efeitos colaterais. Clorambucil foi eficaz em 78,5 por cento (11/14) e induziu remissão da doença em 43 por cento (6/14) dos pacientes; ciclosporina foi eficaz em 57 por cento (8/14) dos pacientes. Clorambucil e ciclosporina A foram suspensos devido a efeitos colaterais em 21 por cento (leucopenia) e em 57 por cento (nefrotoxicidade, 36 por cento e complicações gastrointestinais, 21 por cento) dos pacientes, respectivamente. Nenhum caso de malignidade foi observado. 36 por cento (16/44) olhos tiveram acuidade visual final <0,1, sendo que 69 por cento (11/16) já apresentavam esta acuidade na primeira consulta. CONCLUSÃO: Este estudo reforça dados de literatura que o clorambucil induz remissão da doença de Behçet enquanto a ciclosporina A é efetiva, porém efeitos colaterais limitam o seu uso. A terapia com clorambucil pode ser uma opção a ser considerada em pacientes com uveíte refratária associada à doença de Behçet.

Fundus-based and electroretinographic strategies for stratification of late-stage Vogt-Koyanagi-Harada disease patients.

PURPOSE: To propose an analytic framework for ocular fundus alterations in late-stage Vogt-Koyanagi-Harada (VKH) disease, to describe the characteristics of overall retinal function as measured with full-field electroretinography (ERG), and to correlate the intensity of the fundus changes with full-field ERG alterations and to stratify patients accordingly. DESIGN: Cross-sectional case series. METHODS: Forty-seven eyes of 26 patients with late-stage VKH disease (> 6 months past disease onset) followed-up at the University of São Paulo School of Medicine underwent fundus photography within 2 months of a full-field ERG examination, both according to predefined protocols. Fundus pictures were evaluated by two observers regarding diffuse fundus depigmentation, nummular lesions, pigment clumps, and subretinal fibrosis, and an overall analysis classified the fundus changes as mild, moderate, or severe. Full-field ERG results were analyzed according to fundus-based stratification and also were stratified into 3 groups solely on the basis of decreasing amplitudes (ERG based or cluster stratification). The concordance between fundus-based and full-field ERG-based stratification strategies was estimated. RESULTS: Overall fundus grading showed substantial interobserver concordance (kappa = 0.78). Comparison of full-field ERG parameters of the three fundus-based stratified groups showed diffusely diminished amplitudes with preservation of implicit times (P < .05). Fundus-based and full-field ERG-based stratification strategies also showed substantial concordance (kappa = 0.68). CONCLUSIONS: The analytic framework for fundus findings proposed in this study seems reproducible and useful, because the severity categories do correlate with retinal function as measured by full-field ERG. This system may allow more precise exchange of information between practitioners as well as researchers with regard to identifying patients with greater retinal compromise rapidly as well as in comparison of outcomes of different treatment regimens.

Revised diagnostic criteria for vogt-koyanagi-harada disease: considerations on the different disease categories.

PURPOSE: To evalulate the applicability of the Revised Diagnostic Criteria for Vogt-Koyanagi-Harada (VKH) disease to Brazilian patients and to verify the association between different disease categories, clinical parameters, and the presence of HLA-DRB1*0405. DESIGN: A retrospective observational case series. METHODS: Medical charts of 67 patients (10 to 64 years in age; 12 men and 55 women), from the Uveitis Service, Hospital das Clínicas, University of São Paulo School of Medicine (HCFMUSP), São Paulo, Brazil were reviewed. Patients, previously diagnosed with VKH disease using criteria proposed by the American Uveitis Society, underwent retrospective classification based on the Revised Diagnostic Criteria. The degree of concordance was assessed. At presentation, 46 patients (69%) were in the early phase. In this group, the mean time from disease onset to treatment was 15 days (range, one to 30 days). Forty-eight patients (72%) were typed for HLA-DRB1*0405 by polymerase chain reaction-sequence specific primer and polymerase chain reaction-sequence-specific oligonucleotides primer. Disease categories, phase at initial presentation, and ocular complications were analyzed. RESULTS: There was a 100% of concordance between the two criteria. Disease was classified as complete in 10 patients (15%), incomplete in 37 patients (55%), and probable in 20 patients (30%). In each group, respectively, 90%, 76%, and 45% were in the early phase at presentation (P = .017). There was no association between disease categories, the presence of HLA-DRB1*0405, and clinical parameters. CONCLUSION: The Revised Diagnostic Criteria proved useful for diagnosis of VKH disease in Brazilian patients. The present retrospective study did not find any association between disease category and severity parameters. To better understand the relevance of disease categories, a minimum follow-up period to categorize patients should be included in future prospective studies.

Optical coherence tomography of a subretinal granuloma in simultaneous visceral and ocular larva migrans.

BACKGROUND: Ocular toxocariasis is usually a unilateral posterior uveitis in otherwise asymptomatic children. The authors report the rare occurrence of presumed ocular toxocariasis presenting as a juxtapapillary lesion in a 52-year-old woman with systemic manifestations of visceral larva migrans. CASE REPORT: A 52-year-old woman presented with blurred vision in her right eye for 2 months. She shared her bedroom with two puppies. Best-corrected visual acuity was 20/20 in both eyes; slit-lamp examination was unremarkable. Funduscopy revealed a whitish, elevated, juxtapapillary retinochoroidal lesion of approximately one disk diameter size with macular star formation. She also developed severe respiratory distress and diarrhea. An intense eosinophilia was detected. Investigation included a liver biopsy positive for Toxocara antigens upon staining with chromogen 3,3'-diaminobenzidin and anti-Toxocara immunoglobulin G >10,240 (enzyme-linked immunosorbent assay). Treatment with albendazole and corticosteroids was implemented. Third generation optical coherence tomography (Stratus Tomographer, Model 3,000, Carl Zeiss Ophthalmic Systems, Inc., Dublin, CA) (OCT) of the macular area was unremarkable, except for a slight increase in retinal thickness as it approached the inflammatory lesion. Two months after treatment, there was a hypopigmented scar with localized condensed vitreous opacities. The OCT demonstrated traction along the vitreoretinal interface as the inflammation waned. A conservative approach was maintained as visual acuity remained stable. CONCLUSION: OCT imaging may offer a practical means of locating and staging posterior pole lesions due to ocular toxocariasis.

[Idiopathic orbital inflammation with extraorbital extension: case report]. / Inflamação idiopática da órbita com extensão extra-orbital: relato de caso.

The authors report a case of a patient with idiopathic orbital inflammation with extension beyond the orbit. Biopsy was performed to confirm the diagnosis of idiopathic orbital inflammation and computed tomography demonstrated the extraorbital extension. Treatment with methotrexate and radiotherapy was used.

Inflamação idiopática da órbita com extensão extra-orbital: relato de caso / Idiopathic orbital inflammation with extraorbital extension: case report

Relato de caso de uma paciente com inflamação idiopática da órbita com extensão extra-orbital. Foi realizada biópsia para confirmar o diagnóstico e a tomografia computadorizada demonstrou o comprometimento extra-orbital do processo inflamatório. O tratamento foi feito com metotrexato e radioterapia.

The authors report a case of a patient with idiopathic orbital inflammation with extension beyond the orbit. Biopsy was performed to confirm the diagnosis of idiopathic orbital inflammation and computed tomography demonstrated the extraorbital extension. Treatment with methotrexate and radiotherapy was used.

Causas das uveítes em serviço terciário em São Paulo, Brasil / Causes of uveitis in a tertiary center in São Paulo city, Brazil

OBJETIVO: Analisar as causas das uveítes em pacientes atendidos no Serviço de Uveítes do HC-FMUSP no período de fevereiro a agosto de 2002. MÉTODOS: Realizou-se estudo retrospectivo baseado em prontuários de 262 pacientes que compareceram no serviço no período acima. Os seguintes dados foram analisados: idade, sexo, diagnósticos anatômico e etiológico, atividade da doença e complicações oculares. RESULTADOS: A idade média dos pacientes foi de 41 anos, sendo 60 por cento do sexo feminino e 40 por cento do masculino. O diagnóstico anatômico distribuiu-se em anterior (20 por cento), intermediário (4,5 por cento), posterior (39,7 por cento) e difuso (31,3 por cento). A etiologia foi determinada em 79,4 por cento dos casos, sendo os diagnósticos mais freqüentes toxoplasmose (22 por cento), síndrome de Vogt-Koyanagi-Harada (13 por cento) e doença de Behçet (10 por cento). Causas infecciosas foram observadas em 79 por cento das uveítes posteriores, ao passo que causas não infecciosas em 61 por cento das uveítes anteriores e 73 por cento das difusas. Foram observados alguns diagnósticos raros, tais como uveíte associada ao HTLV-I/II, síndrome do anticorpo antifosfolípide e retinopatia auto-imune. Quanto à atividade de doença ocular, a doença estava ativa em 15 por cento dos pacientes e inativa em 85 por cento. As complicações mais comuns foram catarata (42 por cento) e glaucoma (13 por cento). CONCLUSÕES: Estudos epidemiológicos podem refletir diferentes padrões de etiologia das uveítes; no entanto eles podem mostrar características particulares de cada centro (terciário, critério de diagnóstico, interesses específicos). O presente estudo demonstra a importância das uveítes endógenas (síndrome de Vogt-Koyanagi-Harada e doença de Behçet), assim como das uveítes infecciosas (toxoplasmose e toxocaríase) em nosso meio.

Estudo da uveíte na artrite reumatóide juvenil / Study of iveitis in juvenile rheumatoid arthritis

Objetivo: Estudar a incidência de uveíte em pacientes com artrite reumatóide juvenil (ARJ) do Hospital das Clínicas da Faculdade de Medicina da USP bem como a freqüência da uveíte nos diferentes subtipos de ARJ e possíveis fatores de risco para desenvolvimento da uveíte. Métodos: Foi realizado exame oftalmológico completo em 160 crianças com idade inferior a 16 anos e diagnóstico de ARJ, sendo 52 com a forma sistêmica, 35 com a forma poliarticular e 73 com a forma pauciarticular. Resultados: Na forma sistêmica observou-se fator anti-núcleo (FAN) positivo em 8,5 por cento e fator reumatóde (FR) positivo em 2,2 por cento; na forma poliarticular, FAN e FR foram positivos em 8,6 por cento; e na forma pauciarticular encontrou-se FAN positivo em 25,8 por cento e FR positivo em 0 por cento. Na forma sistêmica näo foi observado nenhum tipo de uveíte. Na forma poliarticular foi encontrada iridociclite bilateral em 5,7 por cento, sendo que um deles evoluiu com catarata e ceratopatia em faixa em ambos os olhos. Na forma pauciarticular foi observada iridociclite em 6,8 por cento, tendo um caso unilateral e quatro bilaterais, tendo um olho evoluído com catarata. Conclusöes: A incidência de uveíte foi de 4,4 por cento, acometendo principalmente os portadores da forma pauciarticular. FAN positivo e idade do início da artrite foram fatores de risco para o desenvolvimento da uveíte.

Manifestaçöes oculares na dermatomiosite juvenil / Ocular manifestations in juvenile dermatomyositis

Dermatomiosite juvenil é uma doença multissistêmica rara, com envolvimento principal de pele e músculos. Alteraçöes oculares säo descritas nesta doença. O presente trabalho avalia as manifestaçöes oculares em 18 pacientes do HC da FMUSP. Alteraçöes palpebrais como heliotropo, dilataçäo e tortuosidade dos vasos e blefarite foram encontradas em metade dos pacientes. Outras alteraçöes encontradas foram: epiteliopatia puntata e catarata. Nenhuma alteraçäo de motilidade ocular extrínseca e de retina foi detectada. A maioria dos pacientes apresentavam-se na fase inativa da doença e sob uso de corticosteróide, explicando a ausência de alteraçöes retinianas. As alteraçöes retinianas. As alteraçöes palpebrais säo descritas com maior frequência

Estudo epidemiologico das uveites / Epidemiological study of the uveitis

Uveite, inflamacao intra-ocular, e importante causa de cegueira, sendo responsavel por 5 a 20 por cento das causas de cegueira nos Estados Unidos. Estudos epidemiologicos sao importantes para o melhor entendimento dos fatores etiopatogenicos da doenca. Fatores geograficos, ambientais, culturais, geneticos, assim como mudanca dos padroes de doenca, novos metodos diagnosticos, novas terapias, influenciam a prevalencia e incidencia de varias uveites...

Comparaçäo do efeito do maleato de timolol e pilocarpina na queda da pressäo intra-ocular / Comparative effect of timolol maleate and pilocarpine in the reduction of the intra-ocular pressure

Os autores analisam o efeito comparativo de pilocarpina e maleato de timolol sobre a pressäo intra-ocular (PIO) de 35 pacientes, 62 olhos portadores de glaucoma crônico simples ou hipertensäo ocular. Quinze pacientes, 28 olhos, receberam pilocarpina 2% quatro vezes ao dia e apresentaram ao final de 18 semanas de tratamento uma reduçäo de 8,04mmHg na PIO. No grupo dois 20 pacientes, 34 olhos foram tratados com maleato de timolol 0,25% a 0,5% em uma ou duas aplicaçöes diárias e apresentaram ao final do tratamento reduçäo de 9,00mmHg na PIO. Quanto à presença de efeitos colaterais e desconforto à droga, 62,50% dos pacientes tratados com pilocarpina apresentaram queixas (embaçamento transitório da visäo, hiperemia, fotofobia, diplopia), enquanto apenas 8,69% dos pacientes tratados com maleato de timolol queixaram-se de desconforto (prurido ocular, embaçamento visual e hiperemia). Os autores concluem que näo houve diferença estatisticamente significante no que se refere à eficácia de tratamento entre os dois grupos e que o grupo tratado com maleato de timolol apresentou boa adaptaçäo ao tratamento, com tolerabilidade significativamente melhor do que o outro grupo